Zipvert Tablet MD contains a combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg, formulated to manage and prevent motion sickness and vertigo-related symptoms. Cinnarizine, a selective calcium channel blocker, acts by inhibiting the vestibular system's overstimulation, thereby reducing nausea, vomiting, and dizziness associated with vestibular disorders. Dimenhydrinate, an antihistamine with anticholinergic properties, further alleviates motion sickness symptoms by blocking histamine H1 receptors and reducing vestibular stimulation. This synergistic combination provides effective relief from nausea, vomiting, and dizziness caused by motion sickness, labyrinthitis, Meniere’s disease, and other vestibular disturbances. Zipvert Tablet MD is indicated for adults and children above 12 years of age and should be administered as per the prescribed dosage to minimize adverse effects. Common side effects may include drowsiness, dry mouth, and gastrointestinal discomfort. Caution is advised in patients with glaucoma, asthma, or prostatic hypertrophy, and it should be used under medical supervision in pregnant or lactating women. Patients are advised to avoid alcohol and activities requiring mental alertness while on therapy due to potential sedation. Zipvert Tablet MD offers a comprehensive approach to managing vestibular disorders by combining the benefits of Cinnarizine and Dimenhydrinate in a single tablet.